From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
17 05 2021
Historique:
received: 09 04 2021
revised: 07 05 2021
accepted: 07 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 27 10 2021
Statut: epublish

Résumé

In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.

Identifiants

pubmed: 34067729
pii: cells10051225
doi: 10.3390/cells10051225
pmc: PMC8157002
pii:
doi:

Substances chimiques

Antineoplastic Agents, Alkylating 0
Biomarkers, Tumor 0
Isocitrate Dehydrogenase EC 1.1.1.41
Temozolomide YF1K15M17Y

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : Project-ID 404521405, SFB 1389 - UNITE Glioblastoma, Work Package A04

Références

Nature. 2013 Sep 19;501(7467):373-9
pubmed: 23995685
Tumour Biol. 2014 Jun;35(6):5911-20
pubmed: 24590270
Neuro Oncol. 2019 Feb 14;21(2):189-200
pubmed: 30184215
Neuro Oncol. 2007 Jul;9(3):271-9
pubmed: 17504928
Neuro Oncol. 2004 Jan;6(1):28-32
pubmed: 14769137
Neoplasia. 2020 Sep;22(9):431-440
pubmed: 32652442
Neuro Oncol. 2010 Jul;12(7):745-55
pubmed: 20388696
BMJ Open. 2017 Jun 10;7(6):e014961
pubmed: 28601826
Neoplasia. 2017 Apr;19(4):364-373
pubmed: 28319810
Br J Cancer. 2011 Mar 15;104(6):968-70
pubmed: 21326241
Cold Spring Harb Symp Quant Biol. 2005;70:99-109
pubmed: 16869743
J Natl Cancer Inst. 2019 Oct 1;111(10):1033-1041
pubmed: 30759236
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5
pubmed: 21289278
Cancer Res. 1998 Oct 1;58(19):4363-7
pubmed: 9766665
Cell Rep. 2019 Apr 16;27(3):971-986.e9
pubmed: 30995489
Oncol Rep. 2020 Nov;44(5):2275-2287
pubmed: 32901889
Cancer Med. 2020 Jan;9(1):3-11
pubmed: 31701682
Ann Neurol. 2007 May;61(5):484-90
pubmed: 17469128
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Nat Commun. 2021 Jan 27;12(1):614
pubmed: 33504762
J Neuropathol Exp Neurol. 2008 May;67(5):456-69
pubmed: 18431251
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Cancer Res. 1987 Sep 15;47(18):4884-9
pubmed: 3621181
Cancers (Basel). 2019 Jun 20;11(6):
pubmed: 31226836
Acta Neuropathol. 2015 Apr;129(4):597-607
pubmed: 25724300
PLoS One. 2015 Feb 23;10(2):e0118781
pubmed: 25706986
Cancer Metab. 2020 Oct 21;8:23
pubmed: 33101674
J Neurooncol. 2012 Mar;107(1):61-7
pubmed: 22037799
Nat Rev Endocrinol. 2014 Mar;10(3):143-56
pubmed: 24393785
Clin Cancer Res. 2009 Nov 15;15(22):7092-8
pubmed: 19861433
Neuro Oncol. 2016 Nov;18(11):1529-1537
pubmed: 27370396
J Neurooncol. 2018 Sep;139(3):563-571
pubmed: 29923053
Nature. 2016 Jan 7;529(7584):110-4
pubmed: 26700815
Neuro Oncol. 2018 Mar 27;20(4):546-556
pubmed: 29016887
Transl Lung Cancer Res. 2020 Oct;9(5):2214-2232
pubmed: 33209645
Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72
pubmed: 2164681
Cancer Chemother Pharmacol. 2014 Oct;74(4):691-7
pubmed: 25062770
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Cancer Res Treat. 2021 Apr;53(2):367-377
pubmed: 33070553
Oncogene. 2007 Jan 11;26(2):186-97
pubmed: 16819506
Oncotarget. 2017 Dec 6;8(68):113090-113104
pubmed: 29348889
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Acta Neuropathol Commun. 2015 Jun 20;3:34
pubmed: 26091668
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Lancet. 2005 Sep 17-23;366(9490):985-90
pubmed: 16168780
Lancet. 2017 Oct 7;390(10103):1645-1653
pubmed: 28801186
Clin Cancer Res. 2019 Sep 15;25(18):5537-5547
pubmed: 31263031
J Biol Chem. 2018 Dec 28;293(52):20051-20061
pubmed: 30381394
Cancer Treat Rev. 1997 Jan;23(1):35-61
pubmed: 9189180
Neoplasia. 2010 Jan;12(1):69-79
pubmed: 20072655
FASEB J. 2018 Jun 7;:fj201800547R
pubmed: 29879375
Cells. 2020 Dec 01;9(12):
pubmed: 33271924
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
Curr Drug Discov Technol. 2020;17(1):2-22
pubmed: 30251606
Pediatr Blood Cancer. 2020 Feb;67(2):e28073
pubmed: 31724813
Cancer Res. 2020 Nov 15;80(22):5098-5108
pubmed: 32958546
Int J Nanomedicine. 2020 May 12;15:3347-3362
pubmed: 32494134
Cancers (Basel). 2019 Jun 24;11(6):
pubmed: 31238504
Neuro Oncol. 2021 Mar 25;23(3):457-467
pubmed: 32678879
Sci Rep. 2019 Mar 15;9(1):4641
pubmed: 30874586
Nat Clin Pract Oncol. 2008 Aug;5(8):476-86
pubmed: 18542116
Am J Cancer Res. 2020 Aug 01;10(8):2242-2257
pubmed: 32905502
Ann Neurol. 2012 Jun;71(6):845-9
pubmed: 22718548
Eur J Cancer. 1993;29A(7):940-2
pubmed: 8499146
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Oncotarget. 2018 Jan 3;9(6):6883-6896
pubmed: 29467937
EMBO Rep. 2011 May;12(5):463-9
pubmed: 21460794
Cancer Res. 2017 Apr 1;77(7):1709-1718
pubmed: 28202508
Mol Cell. 2014 Oct 23;56(2):205-218
pubmed: 25242145
Nature. 2012 Feb 15;483(7390):484-8
pubmed: 22343896
Cell. 2020 Jan 9;180(1):188-204.e22
pubmed: 31883794
J Clin Oncol. 2005 Oct 1;23(28):7178-87
pubmed: 16192602
Nature. 2021 Apr;592(7854):463-468
pubmed: 33762734
Curr Oncol. 2018 Feb;25(1):e33-e39
pubmed: 29507493
Cancer Res. 2018 May 1;78(9):2290-2304
pubmed: 29358170
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Mol Med Rep. 2015 Nov;12(5):7705-11
pubmed: 26459853
Cancer Res. 2017 Aug 1;77(15):4102-4115
pubmed: 28625978
Biochemistry. 1994 Aug 9;33(31):9045-51
pubmed: 8049205
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
Oncotarget. 2016 Jan 19;7(3):2269-83
pubmed: 26745677
Nat Commun. 2017 Oct 20;8(1):1067
pubmed: 29057925
J Neuropathol Exp Neurol. 2013 Apr;72(4):298-306
pubmed: 23481705
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):720-725
pubmed: 32251755
Oncotarget. 2017 May 23;8(21):34896-34910
pubmed: 28432280
Neurooncol Adv. 2020 Jul 16;2(1):vdaa088
pubmed: 32904945
Nature. 2015 Dec 3;528(7580):93-8
pubmed: 26536111
J Neurooncol. 2011 Nov;105(2):241-51
pubmed: 21598070
Cancer. 2003 Apr 15;97(8):1963-8
pubmed: 12673724
Oncogene. 2020 Apr;39(15):3041-3055
pubmed: 32066879
Cancer Cell. 2015 Dec 14;28(6):773-784
pubmed: 26678339
Curr Protoc Immunol. 2015 Nov 02;111:A3.B.1-A3.B.3
pubmed: 26529666
Neurosurg Clin N Am. 2019 Jan;30(1):111-118
pubmed: 30470398
FASEB J. 2014 Mar;28(3):1317-30
pubmed: 24327606
Mol Med. 2019 Nov 14;25(1):49
pubmed: 31726966
Trends Cancer. 2020 May;6(5):380-391
pubmed: 32348734
Neuro Oncol. 2021 Jan 30;23(1):76-87
pubmed: 32882013
Cancer Treat Rev. 2015 Jan;41(1):35-45
pubmed: 25467108
Nat Rev Clin Oncol. 2017 Jan;14(1):57-66
pubmed: 27377132
Nat Rev Clin Oncol. 2015 Jan;12(1):27-41
pubmed: 25286972
Front Pharmacol. 2018 Nov 02;9:1271
pubmed: 30450051
Clin Cancer Res. 2012 Nov 1;18(21):6032-9
pubmed: 22923449
J Neurooncol. 2015 Feb;121(3):479-87
pubmed: 25471051
Nat Rev Cancer. 2005 Dec;5(12):943-55
pubmed: 16294218
Acta Neuropathol. 2010 Apr;119(4):487-94
pubmed: 20127344
Cancers (Basel). 2020 Oct 10;12(10):
pubmed: 33050528
Mol Cancer Res. 2008 Jan;6(1):21-30
pubmed: 18184972
J Cell Physiol. 2019 Jul;234(7):11708-11721
pubmed: 30488547
Crit Rev Toxicol. 2009;39(7):613-26
pubmed: 19650720
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
Clin Cancer Res. 2017 Jul 15;23(14):3489-3498
pubmed: 28364015
Oncotarget. 2016 Nov 15;7(46):74630-74647
pubmed: 27612422
BMC Cancer. 2019 Mar 4;19(1):198
pubmed: 30832617
Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421
pubmed: 30249919
Neurosurg Focus. 2014 Dec;37(6):E12
pubmed: 25434381
Cell. 2018 Sep 20;175(1):101-116.e25
pubmed: 30220459
Neuro Oncol. 2011 Apr;13(4):384-92
pubmed: 21317208
Drug Discov Today. 2021 Feb;26(2):532-541
pubmed: 33157194
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Cancer Res. 2015 Aug 1;75(15):3127-38
pubmed: 26025730
Br J Cancer. 1996 May;73(9):1049-52
pubmed: 8624262
Cancer Res. 2014 Sep 1;74(17):4836-44
pubmed: 25035396
Front Oncol. 2019 Feb 04;9:41
pubmed: 30778375
Cancer Cell Int. 2020 Jan 3;20:1
pubmed: 31908598
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9964-9972
pubmed: 32312817
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Tumour Biol. 2015 Feb;36(2):655-62
pubmed: 25283382
Clin Cancer Res. 2009 Jul 15;15(14):4622-9
pubmed: 19584161
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Clin Cancer Res. 2021 Jan 15;27(2):383-388
pubmed: 32883741
Cancer Res. 2015 Aug 1;75(15):2999-3009
pubmed: 26045167
J Clin Oncol. 2009 Mar 10;27(8):1262-7
pubmed: 19204199
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Oncotarget. 2017 Feb 28;8(9):15827-15837
pubmed: 28178660
Int J Cancer. 2006 Nov 1;119(9):2030-5
pubmed: 16804905
Neuro Oncol. 2013 May;15(5):595-606
pubmed: 23393207
Genes Dis. 2016 May 11;3(3):198-210
pubmed: 30258889
J Neurooncol. 2016 Mar;127(1):165-71
pubmed: 26729269
Cancers (Basel). 2020 Mar 26;12(4):
pubmed: 32224866
Nature. 1969 Jul 12;223(5202):206-7
pubmed: 5791738
PLoS One. 2015 Aug 26;10(8):e0136669
pubmed: 26309255
Neuro Oncol. 2021 Apr 17;:
pubmed: 33864086
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148839
Cancer Res. 2006 Apr 15;66(8):3987-91
pubmed: 16618716
Oncotarget. 2017 Apr 25;8(17):28865-28879
pubmed: 28427200
Neoplasia. 2010 Sep;12(9):727-39
pubmed: 20824049
Oncotarget. 2013 Oct;4(10):1729-36
pubmed: 24077826
J Neurooncol. 2018 Feb;136(3):533-539
pubmed: 29143276
Neuro Oncol. 2012 Feb;14(2):184-91
pubmed: 22166263
Cells. 2020 Jun 03;9(6):
pubmed: 32503220
Front Oncol. 2020 May 22;10:669
pubmed: 32528873
Cancer Res. 2001 Jul 1;61(13):4956-60
pubmed: 11431323
Oncol Rep. 2015 Mar;33(3):1465-74
pubmed: 25585997
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992
pubmed: 26194676
Cancer Res. 2017 Feb 15;77(4):823-826
pubmed: 28159862
Ann Oncol. 2013 Apr;24(4):1112-9
pubmed: 23172636
J Cell Mol Med. 2018 Nov;22(11):5300-5310
pubmed: 30133120
Nat Rev Mol Cell Biol. 2006 May;7(5):335-46
pubmed: 16612326
Target Oncol. 2019 Dec;14(6):657-679
pubmed: 31625002
Neuro Oncol. 2009 Oct;11(5):556-61
pubmed: 19289491
Neuro Oncol. 2021 Jan 30;23(1):53-62
pubmed: 32710757
Clin Cancer Res. 2014 Jun 1;20(11):2898-909
pubmed: 24714777
Cancer Res. 2010 Nov 15;70(22):8981-7
pubmed: 21045145
ACS Omega. 2021 Feb 05;6(6):4289-4299
pubmed: 33644550
Neuro Oncol. 2017 Oct 1;19(10):1316-1326
pubmed: 28419303
Mol Cancer Ther. 2005 Sep;4(9):1364-8
pubmed: 16170028
Neurooncol Pract. 2019 Jul;6(4):264-273
pubmed: 31386080
J Neurooncol. 2020 May;147(3):557-566
pubmed: 32193690
Mol Cell. 2012 Feb 10;45(3):371-83
pubmed: 22325354
Signal Transduct Target Ther. 2019 Dec 17;4:62
pubmed: 31871779
J Clin Oncol. 1998 Nov;16(11):3570-5
pubmed: 9817277
Oncol Lett. 2018 Feb;15(2):2477-2484
pubmed: 29434961
PLoS One. 2018 Aug 28;13(8):e0202860
pubmed: 30153289
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Int J Neurosci. 2020 May 26;:1-9
pubmed: 32378973
Biomedicines. 2019 Nov 27;7(4):
pubmed: 31783653
Neuro Oncol. 2016 Nov;18(11):1559-1568
pubmed: 27154922
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
pubmed: 8948338
Mol Pharm. 2015 Apr 6;12(4):1279-88
pubmed: 25751281
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Clin Cancer Res. 2007 Apr 1;13(7):2038-45
pubmed: 17404084
Exp Mol Med. 2020 Sep;52(9):1496-1516
pubmed: 32943735
Biomedicines. 2020 Jun 04;8(6):
pubmed: 32512726
Neuro Oncol. 2015 Sep;17(9):1275-83
pubmed: 26019185
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
J Neurooncol. 2012 Feb;106(3):643-9
pubmed: 21968943
Nature. 2012 Feb 15;483(7390):474-8
pubmed: 22343901
Proc Natl Acad Sci U S A. 1989 Nov;86(22):8650-4
pubmed: 2682655
Nat Commun. 2013;4:2035
pubmed: 23792809
Cancer Discov. 2020 Nov;10(11):1672-1689
pubmed: 32606138
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
Sci Transl Med. 2012 Jan 11;4(116):116ra5
pubmed: 22238333
Oncotarget. 2013 Oct;4(10):1737-47
pubmed: 24077805
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237

Auteurs

Xueyuan Sun (X)

Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Sevin Turcan (S)

Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH